Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2012;37(4):386–98. https://doi.org/10.1111/j.1365-2710.2011.01323.x.

Article  CAS  PubMed  Google Scholar 

Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab. 2012;14(12):1145–54. https://doi.org/10.1111/dom.12011.

Article  CAS  PubMed  Google Scholar 

Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206.

Article  CAS  PubMed  Google Scholar 

Wu W, Li Y, Chen X, Lin D, Xiang S, Shen F, et al. Effect of Linagliptin on glycemic control in chinese patients with newly-diagnosed, drug-naïve type 2 diabetes mellitus: a randomized controlled trial. Med Sci Monit. 2015;9(21):2678–84.

Article  Google Scholar 

De Meester I, Korom S, Van Damme J, Scharpé S. CD26, let it cut or cut it down. Immunol Today. 1999;20(8):367–75.

Article  PubMed  Google Scholar 

Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012;28(9):1465–74. https://doi.org/10.1185/03007995.2012.714360.

Article  CAS  PubMed  Google Scholar 

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Cochrane database. Syst Rev. 2008;2008(2):CD006739.

Google Scholar 

Smpc (Summary of Product Characteristics) [Internet]. www.medicines.org.uk. 2019 [cited 2023 Oct 18]. Available from: https://www.medicines.org.uk/emc/product/4762/smpc#gref

Tarapués M, Cereza G, Figueras A. Association of musculoskeletal complaints and gliptin use: review of spontaneous reports. Pharmacoepidemiol Drug Saf. 2013;22(10):1115–8. https://doi.org/10.1002/pds.3503.

Article  CAS  PubMed  Google Scholar 

Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: Recommendations and obligations beyond phase 3. Am J Public Health. 2008;98(8):1366–71. https://doi.org/10.2105/AJPH.2007.124537.

Article  PubMed  PubMed Central  Google Scholar 

Cooper ME, Perkovic V, Groop PH, Hocher B, Hehnke U, Meinicke T, et al. Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria. J Hypertens. 2019;37(6):1294–300.

Article  CAS  PubMed  Google Scholar 

Rauch T, Graefe-Mody U, Deacon CF, Ring A, Holst JJ, Woerle HJ, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther. 2012;3(1):1–14. https://doi.org/10.1007/s13300-012-0010-y.

Article  CAS  Google Scholar 

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1–10. https://doi.org/10.1186/s13643-016-0384-4.

Article  Google Scholar 

Bajaj M, Gilman R, Patel S, Kempthorne-Rawson J, Lewis-D’Agostino D, Woerle HJ. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med. 2014;31(12):1505–14. https://doi.org/10.1111/dme.12495.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barnett AH, Huisman H, Jones R, Von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9902):1413–23.

Article  CAS  PubMed  Google Scholar 

Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13(3):258–67. https://doi.org/10.1111/j.1463-1326.2010.01350.x.

Article  PubMed  Google Scholar 

Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obes Metab. 2011;13(7):653–61. https://doi.org/10.1111/j.1463-1326.2011.01391.x.

Article  CAS  PubMed  Google Scholar 

Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes, Obes Metab. 2017;19(11):1610–9. https://doi.org/10.1111/dom.13041.

Article  CAS  PubMed  Google Scholar 

Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14(6):565–74. https://doi.org/10.1111/j.1463-1326.2012.01590.x.

Article  CAS  PubMed  Google Scholar 

Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab. 2012;14(4):348–57. https://doi.org/10.1111/j.1463-1326.2011.01545.x.

Article  CAS  PubMed  Google Scholar 

Ledesma G, Umpierrez GE, Morley JE, Lewis-D’Agostino D, Keller A, Meinicke T, et al. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: a randomized trial. Diabetes Obes Metab. 2019;21(11):2465–73. https://doi.org/10.1111/dom.13829.

Article  CAS  PubMed  Google Scholar 

Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ. Efficacy and tolerability of Linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind. Placebo-Controlled Trial Clin Ther. 2012;34(9):1909-19.e15.

CAS  PubMed  Google Scholar 

McGill JB, Sloan L, Newman J, Patel S, Sauce C, Von Eynatten M, et al. Long-term efficacy and safety of Linagliptin in patients with type 2 diabetes and severe renal impairment a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36(2):237–44. https://doi.org/10.2337/dc12-0706.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1. Diabet Med. 2011;28(11):1352–61. https://doi.org/10.1111/j.1464-5491.2011.03387.x.

Article  CAS  PubMed  Google Scholar 

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA Randomized clinical trial. JAMA. 2019;321(1):69–79.

Article  CAS  PubMed  Google Scholar 

Taskinen M, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65–74.

Article  CAS  PubMed  Google Scholar 

Thrasher J, Daniels K, Patel S, Whetteckey J, Woerle HJ. Efficacy and safety of Linagliptin in Black/African american patients with type 2 Diabetes: a 6-month, randomized, double-blind placebo-controlled study. Endocr Pract. 2014;20(5):412–20.

Article  PubMed  Google Scholar 

Tinahones FJ, Gallwitz B, Nordaby M, Götz S, Maldonado-Lutomirsky M, Woerle HJ, et al. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: two 24-week randomized, double-blind, double-dummy, parallel-group trials. Diabetes Obes Metab. 2017;19(2):266–74. https://doi.org/10.1111/dom.12814.

Article  CAS  PubMed  Google Scholar 

Wang W, Yang J, Yang G, Gong Y, Patel S, Zhang C, et al. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: a multinational 24-week, randomized clinical trial. J Diabetes. 2016;8(2):229–37.